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Abstract
BACKGROUND
Faecal immunochemical test (FIT) has been recommended to assess symptomatic
patients for colorectal cancer (CRC) detection. Nevertheless, some conditions
could theoretically favour blood originating in proximal areas of the
gastrointestinal tract passing through the colon unmetabolized. A positive FIT
result could be related to other gastrointestinal cancers (GIC).
AIM
To assess the risk of GIC detection and related death in FIT-positive symptomatic
patients (threshold 10 μg Hb/g faeces) without CRC.
METHODS
Post hoc cohort analysis performed within two prospective diagnostic test studies
evaluating the diagnostic accuracy of different FIT analytical systems for CRC
and significant colonic lesion detection. Ambulatory patients with
gastrointestinal symptoms referred consecutively for colonoscopy from primary
and secondary healthcare, underwent a quantitative FIT before undergoing a
complete colonoscopy. Patients without CRC were divided into two groups
(positive and negative FIT) using the threshold of 10 μg Hb/g of faeces and data
from follow-up were retrieved from electronic medical records of the public
hospitals involved in the research. We determined the cumulative risk of GIC,
CRC and upper GIC. Hazard rate (HR) was calculated adjusted by age, sex and
presence of significant colonic lesion.
RESULTS
We included 2709 patients without CRC and a complete baseline colonoscopy,
730 (26.9%) with FIT ≥ 10 µgr Hb/gr. During a mean time of 45.5 ± 20.0 mo, a GIC
was detected in 57 (2.1%) patients: An upper GIC in 35 (1.3%) and a CRC in 14
(0.5%). Thirty-six patients (1.3%) died due to GIC: 22 (0.8%) due to an upper GIC
and 9 (0.3%) due to CRC. FIT-positive subjects showed a higher CRC risk (HR 3.8,
95%CI: 1.2-11.9) with no differences in GIC (HR 1.5, 95%CI: 0.8-2.7) or upper GIC
risk (HR 1.0, 95%CI: 0.5-2.2). Patients with a positive FIT had only an increased
risk of CRC-related death (HR 10.8, 95%CI: 2.1-57.1) and GIC-related death (HR
2.2, 95%CI: 1.1-4.3), with no differences in upper GIC-related death (HR 1.4,
95%CI: 0.6-3.3). An upper GIC was detected in 22 (0.8%) patients during the first
year. Two variables were independently associated: anaemia (OR 5.6, 95%CI: 2.2-
13.9) and age ≥ 70 years (OR 2.7, 95%CI: 1.1-7.0).
CONCLUSION
Symptomatic patients without CRC have a moderate risk increase in upper GIC,
regardless of the FIT result. Patients with a positive FIT have an increased risk of
post-colonoscopy CRC.
Key words: Colonoscopy; Colorectal cancer; Faecal immunochemical test; Gastric cancer;
Gastroesophageal cancer; Gastrointestinal cancer; Symptoms
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Core tip: Our study, evaluates for the first time whether symptomatic patients with a
positive faecal immunochemical test (FIT) result, no colorectal cancer (CRC) and a
complete exploration of the colon have increased risk of related gastrointestinal cancer
(GIC) detection or death. We found that this cohort of patients only have an increased
risk of related CRC and death when compared with the cohort with a negative FIT result.
Although the risk of upper GIC is higher than expected, the probability of detecting an
upper GIC is unrelated to the FIT result and only associated with anaemia and advanced
age.
Citation: Pin-Vieito N, Iglesias MJ, Remedios D, Rodríguez-Alonso L, Rodriguez-Moranta F,
Álvarez-Sánchez V, Fernández-Bañares F, Boadas J, Martínez-Bauer E, Campo R, Bujanda
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INTRODUCTION
The use of quantitative faecal immunochemical test (FIT) is increasing outside the
screening setting. FIT has proved its ability to identify which symptomatic patients
are  more  likely  to  have  an  underlying  colorectal  cancer  (CRC)  or  even  other
significant colonic lesions (SCL). Therefore, it is useful to improve the suitability of
referrals for investigation of abdominal symptoms[1].
In this sense, the National Institute for Health and Care Excellence (NICE) has
recently recommended adoption of FIT in primary care to guide referral for suspected
CRC in people without rectal bleeding who have unexplained symptoms but do not
meet  the  criteria  for  a  suspected cancer  pathway referral,  and results  should be
reported using a threshold of 10 μg Hb/g faeces[2,3].
This has been possible due to the progressive replacement of the guaiac-based
faecal occult blood test by the immunochemical-based test. FIT reacts with human
globin, a protein digested by enzymes in the upper gastrointestinal tract (GIT), so it
should have greater specificity to detect lower GIT lesions than guaiac-based tests and
is not modified by diet[4,5]. Nevertheless, some conditions (e.g., altered bowel habit,
prior gastrectomy) could theoretically favour blood originating in proximal areas of
the GIT passing through the colon unmetabolized. A previous systematic review led
to the conclusion that there is  insufficient evidence to recommend for or against
routine esophagogastroduodenoscopy (EGD) in patients with a positive faecal occult
blood test followed by negative colonoscopy[6].
However, all the studies included were mainly based on faecal occult blood test
that used the guaiac method or had been performed in a screening setting. Thus,
conclusions drawn from these data cannot be extrapolated to the application of FIT in
symptomatic patients. These patients may require additional diagnostic workup as
long as complaints could be related to bleeding lesions located in the GIT proximal to
the colon[7]. Thus, we aim to assess the risk of gastrointestinal cancers (GIC) detection
and related death in symptomatic patients with a positive determination of FIT (≥ 10
μg  Hb/g  faeces)  without  CRC  at  baseline  quality  colonoscopy  and  to  evaluate
whether it might be worthwhile to perform additional evaluations to detect an upper
GIC.
MATERIALS AND METHODS
Study design
This is a post hoc cohort analysis performed within two prospective diagnostic test
studies evaluating the diagnostic accuracy of different FIT analytical systems for CRC
and SCL detection[8,9].
We  followed  the  Strengthening  the  Reporting  of  Observational  studies  in
Epidemiology statement to conduct and report our study[10]. The main characteristics
of the different cohorts have been detailed elsewhere[8,9].
Inclusion and exclusion criteria
The  study  population  consisted  of  ambulatory  patients  with  gastrointestinal
symptoms referred  consecutively  for  colonoscopy from primary  and secondary
healthcare in ten out of the thirteen hospitals that took part in the primary studies.
Patients included in the analysis underwent a quantitative FIT before undergoing a
complete  colonoscopy.  Patients  were  excluded from this  analysis  if  a  CRC was
detected on baseline exploration or the colonoscopy was incomplete. A colonoscopy
was  considered  complete  if  more  than  90%  of  the  mucosa  could  be  evaluated
according to the Aronchick scale and caecal intubation was achieved[11]. In addition,
patients  were  excluded  from  this  analysis  if  follow-up  after  colonoscopy  was
insufficient (< 2 years) or a GIC was diagnosed before basal colonoscopy.
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Definition of cohorts
Patients were divided into two groups (positive and negative FIT) using the threshold
of 10 μg Hb/g of faeces. All individuals collected a stool sample from one bowel
movement  without  specific  diet  or  medication  restrictions  before  colonoscopy.
Characteristics of the different FIT system used are shown in Table 1. Estimates of
faecal haemoglobin (f-Hb) were quantitated as µg Hb/g of faeces so that results could
be compared across analytical systems[12].
Colonoscopy and pathology
The colonoscopist was blinded to the FIT results. The bowel was cleansed and sedated
as  previously  reported  and  all  colonoscopies  were  performed  by  experienced
endoscopists  who  reported  any  colorectal  lesion  and  obtained  biopsies  if
appropriate[13].  All  polyps  were  removed  either  upon  baseline  exploration  or
afterwards.
SCL was defined as advanced adenoma (any adenoma ≥ 10 mm, with high-grade
dysplasia or villous histology), histologically confirmed colitis (any aetiology), polyps
≥ 10 mm, polyposis (> 10 polyps of any histology), complicated diverticular disease
(bleeding, diverticulitis), bleeding angiodysplasia and colonic ulcer. Any other colonic
lesion was considered non-significant.
Follow up and main outcome
The main outcomes of this analysis are GIC detection and GIC-related death. Data
from follow-up were retrieved from electronic medical records of the public hospitals
involved in the research. For all patients, cancer diagnoses of any aetiology were
recorded. We classified all cancers that could justify the presence of blood in the GIT
as a GIC: Oral, throat, oesophageal, gastric, intestinal and CRC. We defined an upper
GIC as a cancer that can be detected in an EGD exploration: Oesophageal, gastric,
duodenal or ampullary cancer. The cause and date of death were recorded. We pooled
the different causes of death into five categories: related to (1) GIC, (2) Upper GIC, (3)
CRC, (4) Global cancer or (5) Global death.
Data analysis
We first performed a descriptive analysis of the cohorts included in the analysis. We
determined whether there were differences using the Chi-square and student t test in
the qualitative and quantitative variables, respectively. We calculated cumulative risk
and number of cases per 1000 patient-years and its 95% confidence interval (CI).
Differences  in  cumulative  risk  were  analysed  with  the  Chi-square  test  and
Cochran–Mantel–Haenszel  statistics  and expressed as  the risk ratio  (RR) and its
95%CI. In order to control confounding variables, age, sex and SCL, we performed a
Cox regression analysis to determine the hazard ratio (HR) of detecting a new cancer
and cancer-related death respectively.
In order to determine whether there was an association between the baseline faecal
haemoglobin concentration and length of time to GIC detection, we performed a
descriptive  analysis  and  a  correlation  analysis.  We  determined  the  Spearman
correlation coefficient (r).
Finally, we evaluated which variables were associated with detection of any upper
GIC during the first year after baseline colonoscopy. In this respect, we determined
which variables had a statistically significant association with detection of an upper
GIC using the Chi-square and the Cochran–Mantel–Haenszel statistics and expressed
the  differences  as  RR  and  its  95%CI.  We  included  variables  with  a  statistically
significant association (P  < 0.05) in a multivariate logistic regression analysis and
expressed the association as the odds ratio (OR) and 95%CI. Statistical analysis was
performed using SPSS statistical software, version 15.0 (SPSS Inc., Chicago, IL, USA)
The  statistical  methods  of  this  study were  reviewed by  Noel  Pin  Vieito  from
Complexo Hospitalario Universitario de Ourense.
RESULTS
Participants and descriptive data
We excluded 1347 patients out of the 4056 symptomatic patients initially included in
both studies, yielding a final sample of 2709 (Figure 1).
Of these participants, 1979 (73.1%) and 730 (26.9%) had a negative and positive FIT,
respectively. The cohorts included were different in terms of age, sex, healthcare
referring to colonoscopy, colonoscopy indication, findings in baseline exploration and
length of follow-up as shown in Table 2.
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Table 1  Characteristics of the different faecal immunochemical tests evaluated
Ref. Country Analytical system for estimation of faecal haemoglobin concentration
Cubiella et al[9], 2016 (DC) Spain OC-Sensor: 100%
Rodríguez-Alonso et al[8], 2015 Spain OC-Sensor: 100%
Cubiella et al[9], 2016 (VC) Spain OC-Sensor: 49.7%; OC-Auto 3 Latex 13.8%; FOB Gold 2.4%; Linear i-FOB 34.1%
Overall Spain OC-Sensor: 81.8%; OC-Auto 3 Latex 5.0%; FOB Gold 0.9%; Linear i-FOB 12.3%
DC: Derivation cohort; VC: Validation cohort.
Cancer incidence and death
During a mean time of 45.5 ± 20.0 mo, a GIC was detected in 57 (2.1%) patients: An
upper  GIC  (six  oesophageal  carcinomas,  25  gastric  carcinomas,  one  duodenal
adenocarcinoma, two ampullary carcinomas and one duodenal GIST) in 35 (1.3%), a
CRC  in  14  (0.5%)  and  other  GIC  (three  cholangiocarcinomas,  two  small  bowel
adenocarcinomas,  one  small  bowel  lymphoma,  one  lingual  carcinoma  and  one
piriform sinus carcinoma) in 8 (0.3%). The distribution of the GIC according to the FIT
result is shown in Figure 1. Thirty-six patients (1.3%) died due to GIC: 22 (0.8%) due
to an upper GIC and 9 (0.3%) due to CRC. Finally, 205 (7.6%) patients developed a
cancer and 197 (7.3%) died, 98 (3.5%) due to cancer. Cumulative risk and number of
cancers and death per 1000 patient-years is shown in Table 3.
Patients with positive FIT showed greater GIC risk (≥ 10 µg/g of faeces = 3.2%, < 10
µg/g of faeces = 1.7%; RR 1.9, 95%CI: 1.1-3.2) and GIC-related mortality (≥ 10 µg/g of
faeces = 2.3%, < 10 µg/g of faeces = 1.0%; OR 2.5, 95%CI: 1.3-4.6). In the subgroup
analysis, patients in the positive FIT cohort had an increased risk of CRC (≥ 10 µg/g of
faeces = 1.1%, < 10 µg/g of faeces = 0.3%; RR 3.6, 95%CI: 1.3-10.5) and CRC-related
mortality (≥ 10 µg/g of faeces = 1.0%, < 10 µg/g of faeces = 0.1%; RR 9.5, 95%CI: 2.0-
46.2) but no differences in upper GIC or upper GIC-related mortality as shown in
Table 3. However, in the Cox’s proportional multivariate regression analysis, patients
with a positive FIT had only an increased risk of CRC (HR 3.8, 95% CI 1.2-11.9), CRC-
related death (HR 10.8, 95%CI: 2.1-57.1) and GIC-related death (HR 2.2, 95%CI: 1.1-
4.3), after adjusting for confounding variables. The cumulative risk of cancer and
related death calculated in the Cox’s multivariate regression analysis is shown in
Figure 2.
Faecal haemoglobin concentration and time of cancer diagnosis
Figure 3 links time elapsed until diagnosis of each GIC throughout follow-up with the
FIT result. We did not detect a correlation between time to GIC diagnosis (r = -0.1; P =
0.4) or related death (r = -0.2; P = 0.3) and FIT result as shown in Figure 4.
Detection of upper GIC during the first year of follow-up
During the first year after baseline colonoscopy, 22 (0.8%) upper GIC were detected:
17  cases  of  gastric  carcinomas,  4  oesophageal  carcinomas  and  one  ampullary
carcinoma. Only two variables were independently associated with detection of an
upper GIC during the first year: anaemia (OR 5.6, 95%CI: 2.2-13.9), defined as < 11
g/100 mL in men and < 10 g/100 mL in non-menstruating women, and age ≥ 70 years
(OR 2.7, 95%CI: 1.1-7.0), as shown in Table 4.
Diagnosis of gastrointestinal cancer during follow up based on SCL detection at
baseline colonoscopy
The distribution of  GIC according to  FIT result  and presence of  SCL at  baseline
colonoscopy is shown in Figure 5. For each subgroup, the minimum diagnostic yield
of  an  upper  endoscopy  performed  at  the  time  of  FIT  determination,  has  been
calculated assuming a  theoretical  100% sensitivity  for  any esophageal  or  gastric
bleeding tumor developed over the first year since performing baseline colonoscopy.
There were no significant differences in gastroesophageal cancer (GEC) diagnoses
irrespective of FIT result, both in the subgroup of patients with SCL as well as in the
subgroup with normal baseline colonoscopy.
Those results were similar when the analysis was limited to people aged 50 and
older (Figure 6).
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Figure 1
Figure 1  Study population flowchart. CRC: Colorectal cancer; FIT: Faecal immunochemical test; GIC:
Gastrointestinal cancer.
DISCUSSION
Statement of principal findings
Our study, for the first time, evaluates whether symptomatic patients with a positive
FIT result, no CRC and a complete exploration of the colon have increased risk of
related GIC detection or death. We found that this cohort of patients only have an
increased risk of  related CRC and death when compared with the cohort  with a
negative FIT result. There are no differences in the risk of upper GIC between both
cohorts. In addition, we have identified two variables independently associated with
detection of an upper GIC during the first year: Anaemia and advanced age.
Strengths and weaknesses of our study
Our analysis has several strengths. The main one is that we have included a wide
number of symptomatic patients who underwent FIT and colonoscopy in several
public hospitals in Spain. In this sense, we have limited our analysis to subjects with
complete baseline colonoscopy and resection of pre-neoplastic lesions. On the other
hand, we performed follow-up analysis by means of search in the electronic medical
records of our centres linked to the National Health System′s Hospital Discharge
Records Database (CMBD in Spanish), which receives notifications from around 98%
of  Spanish  public  hospitals  that  have  seen  to  more  than  99%  of  the  Spanish
population[14].  Since  2005,  the  CMBD  also  has  partial  coverage  from  private
hospitals[15].
However, the main weakness of our analysis arises from differences between the
cohorts in terms of demographics, basal symptoms, endoscopic findings or follow-up.
Moreover,  the  risk  of  GIC  during  follow-up,  as  expected,  is  low.  To  solve  this
limitation,  we  performed a  Cox  multivariate  regression  analysis  controlling  by
confounding variables and final results are consistent.
Strengths and weaknesses in relation to other studies with discussion of important
differences in results
Our study detected a higher than expected risk of GIC in the patients evaluated,
mainly related to upper GIC and CRC. Estimated 30-year risk of developing an upper
GIC in the United States is 0.98%[16],  which is lower than the risk detected in our
symptomatic cohort. Moreover, the incidence of GEC is also notable even in patients
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Table 2  Characteristics of the individuals included in the analysis, n (%)
Characteristics Overall (n = 2709) FIT < 10 µg/g (n = 1979) FIT ≥ 10 µg/g (n = 730) P value8
Demographic
Age (yr) 62.9 ± 13.5 62.0 ± 13.5 65.5 ± 13.0 < 0.001
Female sex 1432 (52.9) 1084 (54.8) 348 (47.7) 0.001
Primary healthcare referral1 617 (24.2) 397 (21.2) 220 (32.2) < 0.001
Previous colonoscopy2 444 (25.9) 287 (25.8) 157 (26.0) 0.9
Daily using ASA2 330 (19.2) 193 (17.3) 137 (22.7) 0.01
Indications
Rectal bleeding1 1234 (48.3) 843 (45.1) 391 (57.2) < 0.001
Change of bowel habit1 1271 (49.8) 913 (48.8) 358 (52.4) 0.1
Anaemia3,4 368 (16.2) 236 (13.9) 132 (23.1) < 0.001
Abdominal pain5 766 (41.3) 587 (41.8) 179 (40.0) 0.4
Weight loss5 391 (21.1) 301 (21.4) 90 (20.1) 0.6
Basal colonoscopy findings
Benign anorectal lesion2 756 (44.0) 495 (44.4) 261 (43.3) 0.6
Significant colonic lesions6 480 (17.7) 204 (10.3) 276 (37.8) < 0.001
Advanced adenoma1,7 337 (13.2) 139 (7.4) 198 (29.0) < 0.001
Follow-up (mo) 45.5 ± 20.0 47.9 ± 21.2 39.2 ± 14.1 < 0.001
Missing data in
1156,
2992,
3441 and
4Defined as < 11 g/100 mL in men and < 10 g/100 mL in non-menstruating women.
5856 patients.
6Advanced adenoma (≥ 10 mm, villous histology, high-grade dysplasia), polyposis (> 10 polyps of any histology), colitis (any aetiology), polyps ≥ 10 mm,
complicated diverticular disease, colonic ulcer and/or bleeding angiodysplasia.
7Adenoma ≥ 10 mm, villous histology or high-grade dysplasia.
8Differences between both groups in the Chi-square test in the qualitative variables and in the student t test in the quantitative variables. Differences with P
< 0.05 are considered statistically significant. Qualitative variables are expressed as absolute numbers and percentages. Quantitative variables are
expressed as mean and standard deviation. ASA: Acetyl salicylic acid; FIT: Faecal immunochemical test.
with  a  positive  FIT  result  who  were  diagnosed  with  a  SCL  in  the  baseline
colonoscopy, which could theoretically justify the presence of haemoglobin in faeces.
This is related to the lack of specificity of symptoms related to diagnosis of cancer. In
this sense, we believe that most GIC detected are prevalent. As an example, anaemia,
although mainly related to CRC, is related to any GIC with positive predictive values
ranging between 1% and 5% of the population seen in primary healthcare[2].
FIT has been recommended for  adoption in primary care to guide referral  for
suspected colorectal cancer in people without rectal bleeding who have unexplained
symptoms but  do not  meet  the  criteria  for  a  suspected cancer  pathway referral.
Furthermore,  NICE has recommended 10 µg Hb/g of faeces as the threshold for
further evaluation referral[3]. This recommendation is based on the high accuracy of
the test for CRC detection in symptomatic patients[1,17]. However, one practical doubt
when using FIT in symptomatic patients is what to do with “false positive” results.
Most  evidence available  comes from asymptomatic  patients  and suggests  that  a
positive FIT is  not  predictive of  prevalent  GIC[7,18,19].  A recently published study
revealed that only 0.14% of all persons with a positive FIT result were diagnosed with
gastric or oesophageal cancer within 3 years and the risk was similar to the group
with negative FIT[20]. Our study evaluates, for the first time, the risk of GIC after a false
positive FIT result. In this sense, the probability of detecting an upper GIC is not
modified by the FIT result.
It is noteworthy that our study did not exclude patients with high risk symptoms as
rectal bleeding which are outside of NICE recommendation. However, most of the
studies included in the meta-analysis that supports NICE recommendation[1], were not
only concerned with patients with low risk symptoms (i.e., rectal bleeding is described
in several patients in those studies). That clinical concern was highlighted by Fraser[21]
and led to the development of an additional review and meta-analysis to obtain more
information about the accuracy of FIT through the broad spectrum of symptomatic
patients[17]. In our cohort, the risk of GIC cancer tends to be lower in patients with
rectal bleeding. Probably, this is due to this symptom’s being less subjective than
others  like  abdominal  pain  and  more  specific  to  the  colon.  Thus,  unlike  other
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Table 3  Risk of cancer and death according to faecal immunochemical test result
Event Risk Overall (n = 2709) FIT < 10 µg/g (n = 1979) FIT ≥10 µg/g (n = 730) RR1 (95%CI) HR2 (95%CI)
GIC Cumulative3 2.1% (1.6-2.6) 1.7% (1.1-2.3) 3.2% (1.9-4.4) 1.9 (1.1-3.2) 1.5 (0.8-2.7)
GIC Density4 5.6 (4.1-7.0) 4.3 (2.9-5.8) 9.7 (5.8-13.7)
GIC Cumulative death3 1.3% (0.9-1.8) 1.0% (0.5-1.4) 2.3% (1.2-3.4) 2.5 (1.3-4.7) 2.2 (1.1-4.3)
GIC Death density4 3.5 (2.4-4.6) 2.4 (1.3-3.5) 7.1 (3.7-10.5)
Up GIC5 Cumulative3 1.3% (0.9-1.7) 1.2% (0.7-1.6) 1.6% (0.7-2.6) 1.4 (0.7-2.8) 1.0 (0.5-2.2)
Up GIC5 Density4 3.4 (2.3-4.6) 2.9 (1.7-4.1) 5.1 (2.2-8.0)
Up GIC5 Cumulative death3 0.8% (0.5-1.2) 0.7% (0.3-1.0) 1.2% (0.4-2.0) 1.6 (0.7-3.7) 1.4 (0.6-3.3)
Up GIC5 Death density4 2.1 (1.2-3.0) 1.6 (0.8-2.5) 3.8 (1.3-6.2)
CRC Cumulative3 0.5% (0.2-0.8) 0.3% (0.1-0.5) 1.1% (0.3-1.9) 3.6 (1.3-10.5) 3.8 (1.2-11.9)
CRC Density4 1.4 (0.7-2.1) 0.8 (0.2-1.4) 3.4 (1.0-5.7)
CRC Cumulative death3 0.3% (0.1-0.5) 0.1% (0.0-0.2) 1.0% (0.3-1.7) 9.5 (2.0-46.2) 10.8 (2.1-57.1)
CRC Death density4 0.9 (0.3-1.4) 0.3 (-0.1-0.6) 2.9 (0.8-5.1)
Cancer Cumulative3 7.6% (6.6-8.6) 7.3% (6.2-8.5) 8.2% (6.2-10.2) 1.1 (0.8-1.5) 1.1 (0.8-1.5)
Cancer Density4 20.5 (17.7-23.3) 18.8 (15.8-21.9) 25.9 (19.4-32.5)
Cancer Cumulative death3 3.6% (2.9-4.3) 3.2% (2.4-4.0) 4.8% (3.2-6.3) 1.5 (1.0-2.3) 1.4 (0.9-2.2)
Cancer Death density4 9.5 (7.6-11.4) 8.0 (6.0-9.9) 14.7 (9.8-19.6)
Death Cumulative3 7.3% (6.3-8.2) 7.0% (5.9-8.1) 7.9% (6.0-9.9) 1.1 (0.8-1.5) 1.1 (0.8-1.5)
Death Density4 19.2 (16.5-21.8) 17.6 (14.7-20.5) 24.3 (18.1-30.6)
1Differences in cumulative incidence were analysed with the Chi-square and the Cochran–Mantel–Haenszel statistics and expressed as the RR and its
95%CI in the qualitative variables.
2Differences in the risk of cancer and death adjusted by age, sex and presence of significant colonic lesion were analysed with a Cox multivariate regression
and expressed as HR and its 95%CI.
3Cumulative risk is expressed as percentage and its 95%CI.
4Risk density rate is expressed per 1000 patient-years and its 95%CI.
5Defined  as  a  cancer  located  in  the  oesophagus,  stomach,  duodenum  or  ampulla.  CI:  Confidence  interval;  CRC:  Colorectal  cancer;  FIT:  Faecal
immunochemical test; GIC: Gastrointestinal cancer RR: Risk ratio; Up GIC: Upper gastrointestinal cancer.
indications, patients with overt bleeding who underwent a quality colonoscopy that
ruled out CRC were less likely to be diagnosed with an upper GIC.
Although the  risk  is  low,  CRC risk  is  increased in  symptomatic  subjects  with
positive FIT even after a high-quality colonoscopy when compared to patients with a
negative test. This finding is worthy of several comments. CRC detected fall into the
definition of a post-colonoscopy colorectal cancer (PCCRC)[22].  In fact,  the rate of
PCCRC detected, approximately 3%, is located in the expected segment between 2.5%
and 7.7%.  However,  we must  highlight  that  the  risk  of  PCCRC is  higher  after  a
positive FIT, probably due to the higher prevalence in this group of patients. This
finding should be taken into account by physicians if symptoms persist after a normal
colonoscopy. Finally, the risk of PCCRC calculated per 1000 colonoscopies is higher
than the risk previously documented ranging between 0.8 and 2.4[23]. Our population
consists  of  symptomatic  patients  with  a  CRC prevalence  in  the  original  studies
ranging between 3.0% and 13.7%. We therefore suggest that the risk of PCCRC should
be evaluated on the basis of the colonoscopy indication. However, the sample size of
our analysis and the low number of PCCRC detected did not enable us to analyse
additional factors that could predict the risk of PCCRC, such as age, comorbidity and
diverticular disease, or the relationship with baseline symptoms[24].
A recent study conducted in patients taking part in CRC screening has associated
the presence of detectable f-Hb with increased risk of death from a wide range of
causes unrelated to CRC or even GIC[25].  In that study, Libby et al[26]  consider the
possibility of detectable f-Hb originating from subclinical colonic inflammation due to
a generalised inflammatory state. We did not find such an association. However, the
threshold used in our study (10 μg Hb/g faeces) is much lower than the concentration
of approximately 80 μg Hb/g faeces required to attain a positive result by means of
the qualitative method used by Libby et al[26].
Meaning of the study: Possible explanations and implications for clinicians and
policymakers
Early diagnosis of GIC is challenging as long as abdominal symptoms are common,
mostly related to benign diseases and non-specific to a particular cancer.  In fact,
abdominal symptoms are very common among patients with cancer (23%), mainly
WJG https://www.wjgnet.com January 7, 2020 Volume 26 Issue 1
Pin-Vieito N et al. False positive FIT and gastrointestinal cancer
77
Figure 2
Figure 2  Cumulative risk of gastrointestinal cancer and related death. Cumulative risk of gastrointestinal cancer and related death during the first four years after
baseline evaluation according to faecal haemoglobin concentration and adjusted by sex, age and presence of significant colonic lesion. The figure is calculated with a
Cox’s multivariate regression.
related to GIC and CRC in particular[27]. In contrast with breast cancer or melanoma,
GIC have a broad symptom signature with varying predictive value[28]. In order to
reduce  delays  in  patients  with  lower  abdominal  symptoms with  a  low positive
predictive value for CRC, FITs are recommended for adoption in primary care to
guide referral for suspected CRC[3]. Our analysis aims to resolve a frequent issue that
will take place when patients with lower abdominal symptoms are evaluated with a
FIT. Hypothetically, 179-229 out of 1000 symptomatic patients will have a positive FIT
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Figure 3
Figure 3  Time (mo) until gastrointestinal cancer diagnosis according to location, diagnostic test and faecal immunochemical test result. f-Hb: Faecal
haemoglobin (µg Hb/g of faeces).
and colonoscopy without CRC[2]. As our results show, this patient cohort has a similar
risk of GIC as the cohort with a negative FIT. In this situation, an EGD should be
recommended in  patients  with  anaemia especially  if  they are  elderly.  However,
special caution should be taken with the risk of PCCRC after positive FIT and normal
colonoscopy if abdominal symptoms persist or reappear.
Unanswered questions and future research
Our results are the basis to design a large prospective follow-up study including
patients treated in primary healthcare with abdominal symptoms. In these patients,
diagnostic evaluation should not be restricted to GIC. Other abdominal cancers in
addition to benign gastrointestinal diseases should be evaluated to determine the
positive  predictive  value  and  the  best  diagnostic  strategy  for  each  group  of
symptoms.
Additionally, a recent study concluded that endoscopic gastric cancer screening
could be cost-effective if combined with a screening colonoscopy in countries with a
gastric cancer risk ≥ 10 per 100000[29]. Given the gastroesophageal cancer incidences
shown during the first year since FIT determination in our cohort irrespective of SCL
finding in  the basal  colonoscopy,  the cost-utility  of  combining upper  and lower
endoscopies should be investigated also in this setting.
To  summarise,  the  risk  of  GIC  is  higher  than  expected  in  patients  with  low
gastrointestinal symptoms and no CRC detected in a complete colonoscopy. The
probability  of  detecting  an  upper  GIC  is  unrelated  to  the  FIT  result  and  only
associated with the presence of anaemia and advanced age. Finally, the risk of PCCRC
in our study is within the ranges expected and clearly associated with the FIT result.
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Table 4  Factors associated with upper gastrointestinal cancer detection the first year after baseline colonoscopy, n (%)
Upper gastrointestinal cancer Odds ratio (95 %CI)1 Odds ratio (95 %CI)2
Sex
Female (n = 1432) 10 (0.7) 1
Male (n = 1277) 12 (0.9) 1.3 (0.6-3.1)
Age
< 70 yr (n = 1757) 8 (0.5) 1 1
≥ 70 yr (n = 952) 14 (1.5) 3.3 (1.4-7.8) 2.7 (1.1-7.0)
Primary healthcare referral
No (n = 1936) 19 (1.0) 1
Yes (n = 617) 3 (0.5) 0.5 (0.1-1.7)
Rectal bleeding
No (n = 1319) 16 (1.2) 1
Yes (n = 1234) 6 (0.5) 0.4 (0.1-1.0)
Change of bowel habit
No (n = 1282) 12 (0.9) 1
Adequate (n = 1271) 10 (0.8) 0.8 (0.4-1.9)
Anaemia3
No (n = 2077) 13 (0.6) 1 1
Yes (n = 191) 8 (4.2) 6.9 (2.8-17.0) 5.6 (2.2-13.9)
Abdominal pain
No (n = 1319) 12 (1.1) 1
Yes (n = 1234) 5 (0.7) 0.6 (0.2-1.7)
Weight loss
No (n = 1462) 12 (0.8) 1
Yes (n = 391) 5 (1.3) 1.5 (0.5-4.4)
Faecal immunochemical test
< 10 µg/g (n = 1979) 14 (0.7) 1
≥ 10 µg/g (n = 730) 8 (1.1%) 1.5 (0.6-3.7)
Benign anorectal lesion
No (n = 961) 7 (0.7) 1
Yes (n = 756) 6 (0.8) 1.1 (0.4-3.2)
Significant colonic lesion4
No (n = 2216) 16 (0.7) 1
Yes (n = 480) 6 (1.3) (0.7-4.5)
Advanced adenoma5
No (n = 2968) 16 (0.7) 1
Yes (n = 337) 6 (1.8) 2.5 (1.0-6.4)
1Differences were analysed with the Chi-square and Cochran–Mantel–Haenszel statistics and expressed as the odds ratio and its 95%CI.
2Variables with statistically significant differences were introduced in a multivariate logistic regression analysis. The association is expressed as odds ratio
and its 95 %CI.
3Defined as < 11 g/100 mL in men and < 10 g/100 mL in non-menstruating women.
4Advanced adenoma (≥ 10 mm, villous histology, high-grade dysplasia), polyposis (> 10 polyps of any histology), colitis (any aetiology), polyps ≥ 10 mm,
complicated diverticular disease, colonic ulcer and/or bleeding angiodysplasia.
5Adenoma ≥ 10 mm with villous histology or high-grade dysplasia.
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Figure 4
Figure 4  Correlation between faecal haemoglobin concentration and time to gastrointestinal cancer detection and gastrointestinal cancer-related death.
GIC: Gastrointestinal cancer; r: Spearman correlation coefficient.
Figure 5
Figure 5  Gastrointestinal cancer diagnosis during follow up based on faecal immunochemical test result and significant colonic lesion in the basal
colonoscopy. CRC: Colorectal cancer; FIT: Faecal immunochemical test; GITN: Gastrointestinal tract neoplasm; SCL: Significant colonic lesion.
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Figure 6
Figure 6  Minimum diagnostic yield of an upper endoscopy performed at the time of faecal immunochemical test for haemoglobin determination. A: All
subjects; B: subjects aged 50 years old and older. FIT: Faecal immunochemical test for haemoglobin; SCL: Significant colonic lesion; P: Differences were analysed
with the Chi-square statistics.
ARTICLE HIGHLIGHTS
Research background
Faecal immunochemical test for haemoglobin (FIT) is more specific and appears to be equal to or
more sensitive than guaiac-based tests when used for colorectal cancer (CRC) screening. FIT
reacts with human globin, so it should have greater specificity to detect lower gastrointestinal
tract (GIT) lesions than guaiac-based tests. However, a previous systematic review led to the
conclusion  that  there  is  insufficient  evidence  to  recommend  for  or  against  routine
esophagogastroduodenoscopy in asymptomatic patients with a positive faecal occult blood test
followed by negative colonoscopy.
Research motivation
Out of a screening setting, several approaches have been developed to improve the suitability of
referrals for investigation of symptoms suggestive of CRC and reduce delays in diagnosis and
some include using FIT. Therefore, it will be increasingly common for clinicians to face the
uncertainty of a patient with non-specific digestive symptoms, a positive FIT result and normal
colonoscopy.
Research objectives
We  aim  to  assess  the  risk  of  gastrointestinal  cancer  (GIC)  detection  and  related  death  in
symptomatic  patients  with  a  positive  determination of  FIT (threshold 10  μg Hb/g faeces)
without CRC at baseline quality colonoscopy.
Research methods
We  performed  a  post  hoc  cohort  analysis  within  two  prospective  diagnostic  test  studies
evaluating the diagnostic accuracy of FIT for CRC detection. Outpatients with gastrointestinal
symptoms referred consecutively for colonoscopy from primary and secondary healthcare were
divided into two groups (positive and negative FIT) using the threshold of 10 μg Hb/g of faeces
and data from follow-up were retrieved from their electronic medical records. We determined
the cumulative risk of GIC, CRC and upper GIC. Hazard rate was calculated adjusted by age, sex
and presence of significant colonic lesion on basal colonoscopy.
Research results
This study revealed high neoplasia and death rates in our cohort (n = 2709) of people consulting
with a physician for non-acute symptoms suggestive of lower gastrointestinal tract disorders.
FIT-positive patients have higher incidence of GIC during follow-up. However, this did not
result  in  a  statistically  significant  increase  in  the  risk  of  upper  GIC  development  after
multivariate adjustment. Moreover, we found that this cohort of patients only has an increased
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risk of related CRC and death when compared to the cohort with a negative FIT result.
Research conclusions
This study suggests that FIT positivity using the threshold of 10 μg Hb/g of faeces is not enough
to differentiate which patients would benefit from continuing workup to rule out a GIC out of
screening setting. Nevertheless, small amounts of f-Hb may originate in the upper GI tract or the
small bowel and this possibility must be considered along with other false-positive risk factors
when interpreting FIT requested to rule out CRC or another significant colonic lesion.
Research perspectives
We hypothesize that benign lesions (i.e. due to non-steroid anti-inflammatory drugs) are much
more prevalent than GIC in the upper tract regardless of symptoms. Thus, it is much more likely
that a small amount of detectable (unmetabolized) haemoglobin, originally from any kind of
lesion located in the upper tract or the small bowel will be unrelated to a GIC. However, the
study design is not suitable to prove this hypothesis. A large prospective follow-up study which
takes competitive FIT positive causes and other risk factors into consideration would provide a
predictive model to guide decision-making.
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